337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

David Tougeron; Jean Francois Emile; Stephano Kim; Carole Monterymard; Marine Gilabert; BEZ Jérémie; Astrid Lievre; Laetitia Dahan; Pierre Laurent-puig; Laurent Mineur; ROmain Coriat; Jean Louis Legoux; Vincent Hautefeuille; Jean marc Phelip; Thierry Lecomte; Harry Sokol; Claude Capron; Claire Gallois; Violaine Randrian; Come Lepage; Julien Taieb

doi:10.1136/jitc-2020-SITC2020.0337

Citation Tools

Regular and young investigator award abstracts

Clinical trials in progress

337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Tougeron D, Emile JF, Kim S, et al

337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0337

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password